Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success
Advertisement

Related Content

AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City
With Government Support, China Medical City Looks To Separate Itself From The Pack
With Nycomed, Takeda Satifies Both Strategic And Financial Objectives
Takeda's $13.6 Bil. Nycomed Buy Meets Multiple Strategic, Financial Imperatives
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
Takeda Wins One Loses Another With U.S. FDA Approval Of Edarbi, Japan Withdrawal Of Dasen
Takeda's Rozerem Substance Abuse/Toxicity Claims Draw FDA Rebuke
Advertisement
UsernamePublicRestriction

Register

SC077899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel